Trial Profile
An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Epilepsy; Tuberous sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 09 May 2023 Planned End Date changed from 4 Aug 2027 to 13 Aug 2027.
- 17 Jun 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 05 Sep 2019 Planned primary completion date changed from 27 Feb 2019 to 4 Aug 2027.